title: A conversation with Paul Marks. Interview by Ushma S. Neill.
authors.forename: Paul
authors.initials: P
authors.lastname: Marks
mesh_terms: D000970:Antineoplastic Agents / Q000266:history / Q000627:therapeutic use; D002173:Cancer Care Facilities / Q000266:history / Q000458:organization & administration; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000235:genetics / Q000266:history; D006405:Hematology / Q000266:history; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D006877:Hydroxamic Acids / Q000266:history / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy / Q000266:history; D008495:Medical Oncology / Q000266:history*; D014481:United States; D000077337:Vorinostat
chemical_list: D000970:Antineoplastic Agents; D006877:Hydroxamic Acids; D000077337:Vorinostat